GUEST LECTURE
“Optimising Pharmacoeconomic in Health Technology Assessment”
Monday, 16 October 2023 at 13.00-15.00 WIB
BACKGROUND
Pharmacoeconomics plays a crucial role in health technology assessment (HTA) by providing a systematic framework for evaluating the economic aspects of healthcare interventions, particularly pharmaceuticals and medical technologies. HTA is a multidisciplinary process that assesses the value and impact of healthcare interventions on various dimensions, including clinical efficacy, safety, cost-effectiveness, and broader societal and ethical considerations. Pharmacoeconomics is a subset of HTA that focuses specifically on the economic evaluation of pharmaceuticals and their impact on healthcare systems with certain designs of economic evaluation study: Cost-effectiveness analysis (CEA), Cost-minimization analysis (CMA), Budget impact analysis (BIA), etc In the era of universal health coverage or Jaminan Kesehatan Nasional (JKN) in Indonesia, economic evaluation is essential by providing essential tools and insights for policymakers, healthcare professionals, and health systems. As JKN aims to ensure that all individuals have access to quality healthcare services without financial hardship, pharmacoeconomic evaluations help in the allocation of limited resources efficiently.
In the development of vaccines, pharmacoeconomics also plays a significant role, where economic evaluations of vaccines are taken into consideration in decision-making for vaccine development and vaccine policy. For diseases with a high case burden that fall under vaccine-preventable diseases, decision-making in choosing vaccines as the primary prevention strategy requires many considerations, one of which is related to economic evaluation. Given the importance of the role of pharmacoeconomics in Health Technology Assessment (HTA), National Health Insurance (JKN), and even in vaccines, learning about pharmacoeconomics will continue to be relevant for discussion topics.
OBJECTIVES
The objectives of this lecture are:
- Enhancing understanding of the role of economic evaluation in Health Technology Assessment (HTA).
- Identifying challenges in implementing economic evaluation in the era of National Health Insurance (JKN).
- Understanding the role of pharmacoeconomics in the field of vaccines.
ORGANIZER
Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, (FM-PHN) Universitas Gadjah Mada
PARTICIPANTS
Participants invited to take part in the seminar were as follows:
- Postgraduate students (master and doctorate) in Biomedical Science, Clinical Science, and Health Policy
- Researcher and academic staff in the field of Pharmacology, Health economic and Health policy
PLACE AND TIME
- Venue : Kuliah S2 lantai 2, Student Center, FK-KMK UGM
- Day, date : Monday, 16 October 2023
- Time : 13.00-15.00 WIB
- Participants : 60 people + Online participants
AGENDA
“Optimising Pharmacoeconomic in Health Technology Assessment”
Monday, 16 October 2023 at 13.00-15.00 WIB
| Time
(WIB) |
Agenda | Resource Person |
| 13.00-13.30
(30’) |
Economic evaluation for health technology assessment and policy making | A/Prof Natalie Carvalho, Ph.D
(University of Melbourne) |
| 13.30 – 14.00
(30’) |
Challenges of health economic evaluation in Indonesia during the implementation of JKN | Dr. Diah Ayu Puspandari Apt, MBA M.Kes
(Universitas Gadjah Mada) |
| 14.00 – 14.30
(30’) |
Vaccine Economic | Prof. dr. Jarir At Thobari, D.Pharm., Ph.D.
(Universitas Gadjah Mada) |
| 14.30 – 15.00
(30’) |
Discussion | Moderator: dr. Sudi Indra Jaya, M.Biomed |